Keyword: Japan

Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.

Sirt2, an enzyme long of interest to scientists studying metabolism and aging, seems to mediate the process by which the liver processes glucose.

Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.

Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.

Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.

A year ago, Daiichi and partner Plexxikon suspended a trial of a rare cancer candidate on safety advice. Today they posted some very top-line results.

A year after launching its Japanese business, Clinigen has bought Japan’s largest supplier of unlicensed medicines.

With a positive phase 3 trial in hand, Japan’s Daiichi Sankyo plans to file its essential hypertension therapy esaxerenone in its home market.

Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.

Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across trials in Japan.